

Superbugs Spread and Problems of Multidrug-Resistant Infections during Surgery

Asit Kumar Chakraborty*

*Post Graduate Department of Biotechnology and Biochemistry, Oriental Institute of Science and Technology, Genetic Engineering Laboratory, Vidyasagar University, Midnapore, West Bengal, India.

Received May 01, 2018; Accepted May 07, 2018; Published September 22, 2018

ABSTRACT

Surgical procedures are part of our life where normal mechanisms of cells in blood and tissues are hampered creating bacterial infections which are so far controlled by antibiotics since 1950s. Sudden increase in drug resistant pathogens has created a shadow for traditional use of antibiotics before and after surgery. The creation of diversified MDR genes in R-plasmids and integrons (~2-9 kb) is the main cause of drug resistance. However, MDR genes save the gut microbiota for vitamin synthesis whereas vitamins as coenzymes are absolutely needed for >30000 enzymatic reactions for normal human metabolism. Continuous insult of gut microbiota with antibiotics and therefore our intestinal cells have resulted in a tight symbiotic control where creation of a new *mdr* gene against a new antibiotic will take only few days to few weeks. This has happened due to combination of R-plasmids/integrons with F'-plasmid creating MDR conjugative plasmids (50-500 kb) with a more space for 5-15 *mdr* genes, 10-20 Tra genes and 20-60 transposons or IS-elements encoding many integrases, recombinases, DNA polymerases, reverse transcriptases and DNA topoisomerases. Those enzymes are absolutely necessary for new gene creation. Thus drug companies are in fear for antibiotic market and new antibiotic discovery has stopped. However, surgical procedures are increased 50-400 fold as compared to year 2000 data indicating a huge demand of potent antibiotics that could kill superbugs and prevent infection after surgery. WHO has suggested a new direction for antimicrobial research involving heterogeneous phyto-antibiotics, enzybiotics and phage therapy. G-20 leaders are ahead to augment effective one nation research platform for superbug control. We also see gene therapeutics and nanotechnology based drug carriers are in the fore front for the treatment options of MDR infections during surgery. However, MRSA *Staphylococcus aureus*, MDR *Acinetobacter baumannii*, XDR *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* and NDM-1 *Escherichia coli* infections are deadly.

Keywords: MDR infections, Surgery, Symbiosis, Gut microbiota, Biofilm

INTRODUCTION

Human life suffers from many ailments and so far antibiotics and many other antagonistic drugs have cured the diseases since 1928 [1]. Surgery is evident in case of tumors in diverse organs, infections of intestine, blockage of artery and every day accidental fractures or burn [2]. Also in the developed countries cosmetic surgeries are increased many fold [3]. The concept to reduce the surgical infections was came from Dr. Joseph Lister in 1860s when phenol was found good disinfectant for surgical instruments reducing death rate after surgery [4]. Antibiotic were discovered by Nobel Laureates Alexander Fleming and Selman Waksman in 1930s but penicillins and tetracyclines were came to market for all in 1943 after World War II. Ampicillin, amoxicillin, tetracycline, chloramphenicol, sulfamethoxazole, azithromycin, vancomycin, colistin, ciprofloxacin,

streptomycin, rifampicin, norfloxacin, cefotaxime and imipenem are great antibiotics those had safely rule the drug industry for 80 years and perhaps still now if the infections

Corresponding author: Asit Kumar Chakraborty, PhD, Associate Professor of Biochemistry, Post Graduate Departments of Biotechnology and Biochemistry, Oriental Institute of Science and Technology, Genetic Engineering Laboratory, Vidyasagar University, Midnapore 721102, West Bengal, India; E-mail: chakraake@gmail.com

Citation: Chakraborty AK. (2018) Superbugs Spread and Problems of Multidrug-Resistant Infections during Surgery. Int J Surg Invasive Procedures, 1(1): 6-13.

Copyright: ©2018 Chakraborty AK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

were not drug resistant [5]. During surgery prophylactic antibiotic therapy was utilized until in recent years drug resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, etc., were appeared. Hundreds of Beta-lactamase genes are assembled in bacterial plasmids as well as chromosome (as in MRSA *Staphylococcus aureus* infections in burn patients) [1,6,7]. Beta-lactamase gene is *amp* gene which was discovered in 1965 in pBR322 plasmid which was also contain tet gene. Presently, *amp* gene was termed as *bla* gene which was diversified into 20 distinct isomers (**Figure 1**) with no sequence similarities [6]. Cat gene and related *aacC1* or *aacA1* genes acetylate many drug's -OH and -NH₂ groups or aminoglycoside drugs are phosphorylated at -OH group by *strA*, *strB* or related many APH enzymes [1]. Adenylation (*aad* genes) and ribosylation (*arr3* gene) are other rapid mechanisms of inactivation of drugs like streptomycin and rifampicin respectively generating major drug resistant TB and Gonorrhoea [1]. Interestingly, 200 ABC transporter-like drug efflux genes (*tetA/C*, *acrABC*, *mexAB/CD/EF*, *mcr*, *norA*, *mtrCDE*, *macAB*) made most devastation in drug industry as all drug's MIC were increased now-a-day [8].




Figure 1. Too many antibiotic resistant genes were discovered in bacterial plasmids and chromosomes.

Amp gene encodes 286 aa beta-lactamase enzyme that degrades beta-lactam A ring of penicillin. Tet gene kicks out tetracycline drug from bacterial cytoplasm increasing MIC, so no binding to ribosome for inhibiting protein synthesis. *Bla* genes are *blaTEM*, *blaCTX-M*, *blaOXA*, *blaCMY*, *blaAmp-C* and *blaNDM-1*, etc. and also degrade lactam A ring of penicillin, cephalosporins and in some case carbapenems. *Sul1/2* is altered enzymes give resistant to sulfamethoxazole. *Aph* gene encodes phosphotransferases and phosphorylated amikacin and phosphorylated-tobromycin no longer bind ribosome to kill bacteria. *StrA/B* are enzymes that phosphorylate streptomycin and *aacC1/A1* are enzymes that acetylate aminoglycoside antibiotics and in some case ciprofloxacin type fluoroquinolones. *mtrCD* are drug efflux enzymes similar to *mexAB/CD* enzymes or *acrAB/CD* enzymes. Chromosomal *macA/B* genes of *N. gonorrhoeae* inactivate macrolide antibiotics. *Cat* and *Pac*

genes acetylate chloramphenicol and puromycin, respectively.



Figure 2. EM structures of few gram positive and gram negative MDR microorganisms (1-1.5 μm; 6000x).

For example, we see 40% of sea, river and pond household bacteria resistant to ampicillin, amoxicillin and to lesser extent tetracycline and ciprofloxacin, drugs widely used between 1950-1990 [9]. The situation was controlled by development of cefotaxime, meropenem, lomefloxacin, amikacin, colistin and linezolid types drugs [10]. Sadly, in 2009 *blaNDM-1* enzyme gave carbapenem resistant and in 2016 *mcr-1* enzyme gave colistin resistant where as *blaOXA* and *blaCTX-M* new isomers (ESBLs and MBLs) enzymes were mostly resistant to all penicillin's, cephalosporins and carbapenems or related inhibitors. More generously, R-plasmids (5-15 kb) were combined with many integrons (2-4 kb) and F'-plasmid (62 kb) generating MDR conjugative plasmids (50-500 kb) which were very dangerously donating *mdr* genes to most Enterobacteriaceae present in water resources [11]. The point is, most trusted antibiotics are no longer safe as prophylactic therapy during surgery [4,5]. It is also evident that intestinal cells and gut microbiota are in symbiosis to exchange nutrients residing in the biofilm where microbes can withstand low dose of antibiotics but hardly withstand the repeated high doses of antibiotics [12]. Repeated high dose antibiotics is a concern as it affects kidney, liver and most importantly intestinal luminal cells being symbiosis with gut microbiota hampered lowering coenzymes concentration [13]. Such cells now secrete many interleukins and cytokines influenced by bacterial LPS, vitamins and butyrate. Thus such mechanisms demand the life of bacteria and signals to rearrange genes in bacterial plasmids containing many IS-elements, transposons, topoisomerases and integrases [14]. Such hypothesis is true as many plasmids acquired vitamin metabolizing genes and also ¼ genes are unknown but likely are required for gut microbiota protection [15]. In other words, it now only took few weeks to make a new gene to inactivate the action of a new antibiotic which cost two billion dollars for its

development requiring about ten years. This decade is sad for drug companies as no new drugs for bacterial infections but on the other hand, plenty of drugs have been developed recently for cancer, diabetes, hypertension and AIDS. We thus have declared antibiotic void day as present before 1928.

MATERIAL AND METHODS

Purification of superbugs from Ganga river water and Digha sea water

Water from Ganga River was collected at the morning from Babu Ghat (Kolkata, 700001) and Howrah Station River [9]. About 100 µl of water was spread onto 1.5% Luria-Bertani agar plate containing different concentration of antibiotics at 2-50 µg/ml. MDR bacteria were selected in agar-plate containing ampicillin, streptomycin, chloramphenicol, tetracycline or ciprofloxacin at 50, 50, 34 and 20 µg/ml, respectively. As imipenem and meropenem resistant bacteria were present low (0.08-0.2 cfu/ml water), a modified method was followed. 2 ml 5x LB media was added into 10 ml River/Sea water at 2-10 µg/ml concentration and was incubated 24 h to get drug resistant bacteria population [10]. Meropenem resistant bacteria were further selected on tetracycline, chloramphenicol and streptomycin to get the superbugs. Antibiotics were purchased from HiMedia and stored at 2-50 mg/ml at -20°C. Antibiotic papers were also purchased from HiMedia according to CLSI standard. Antibiotic papers are: A-25 (ampicillin), T-10 (tetracycline), AT-50 (aztreonam), COT-25 µg (Cotrimoxazole), Met-10 µg (methicillin), CAZ-30 µg (ceftazidime), LOM-15 µg (lomofloxacin), VA-10 µg (vancomycin), AK-10 µg (Amakacin), TGC-15 µg (tigecycline), LZ-10 µg (linezolid) and IMP-2 µg (imipenem).

Molecular biology techniques

The plasmid DNA was isolated from overnight culture using Alkaline-Lysis Method [15,16]. 16S rDNA gene colour Sanger's di-deoxy sequencing was performed by SciGenom Limited, Kerala, India [17]. PCR amplification was performed using 1 unit Taq DNA polymerase, 20 ng DNA template, 0.25 mM dXTPs, 1.5 mM MgCl₂, for 35 cycles at 95°C/30" (denaturation)-52°C/50" (annealing)-72°C/1.5'. The product was resolved on a 1% agarose gel in 1x TAE buffer at 50 V for 2-4 h and visualized under UV light and photograph was taken [10]. NCBI BLAST analysis was performed for bacterial specific gene analysis (<http://www.ncbi.nlm.nih.gov/blast>) and data was submitted to GenBank. NCBI databases were retrieved using the BLAST programmes [11]. The complete genes are sequenced in plasmids and were analyzed by Seq-2 programme of BLAST [18]. We type the same at the NCBI port (<http://www.ncbi.nlm.nih.gov/nucleotide> or <http://www.ncbi.nlm.nih.gov/protein>) and to BLAST search to type the accession number for protein or DNA into BLAST port-

(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BLASTSearch) [19,20].

RESULTS

The household bacteria in river, sea, pond and rain water are drug resistant and air P10 particulate carry high concentration of MDR bacterial spores. As for example, **Figure 3** showed the drug resistant pattern of a Ganga River superbug and **Figure 4** shows how chloramphenicol resistant cat enzyme formed acetylated chloramphenicol which ran fast in a Thin Layer Chromatography and such drug derivative could not able to inhibit bacterial protein synthesis. The *Escherichia coli* KT-1_mdr was only sensitive to imipenem and linezolid but was resistant to other seven drugs (**Figure 3** and Material and Method). Interestingly, 1,3 di-OH chloramphenicol although bigger (two CH₃CO- group were added in place of two hydrogen atoms) but ran first in Silica gel ascending chromatography in organic solvent (methanol, isopropanol) (**Figure 4**).




Figure 3. Drug sensitivity of *Escherichia coli* KT-1_mdr isolated from Ganga River of Kolkata.




Figure 4. TLC assay of chloramphenicol showing CAT enzyme action on drug.

Such demonstration proved that during surgery antibiotic treatment is not as effective and trustworthy now as before. **Table 1** demonstrated that different cosmetic surgeries were increased in the USA. Breast augmentation in 2017 is 46%

increase as compared to 2000 and similarly Tummy tuck has increased 107% whereas upper arm lift has increased tremendously to 4235%. In 2012, 80 million surgeries were performed in the United States but now worldwide surgeries were increased to 234 million. By 2030, prosthetic joint arthroplasties are projected to increase 3.8 million per year. Surgeries of mouth, GI tract, respiratory tract require high dose cefazolin (2 g) or (+metronidazole) but now blaCTX-M-2/9/15 are expressed in most bacterial plasmids (*E. coli*, *P. aeruginosa*, *A. baumannii* and *S. aureus*). Vancomycin (15 mg/kg) and gentamycin (5 mg/kg) are advised as postoperative infections but vanA gene cluster is very much present in *Enterobacter aerogenes*, *Proteus mirabilis* and *Helicobacter pylori* MDR bacteria. A best pre-operative antibiotic prophylaxis is Clindamycin but aacC1/A1 type acetyl transferases very much active in most bacteria to inactivate such drugs. So Ertapenem (1 g) and Meropenem (0.5 g) are advised now but blaNDM-1 as well as blaKPC-2 is increasing in *Pseudomonas aeruginosa* and *Clostridium difficile*, etc. plasmids (accession nos. KP009590; KP735848; KP265934; KP893385; KJ748372; FJ624872). Alternately, many patients do not tolerate penicillin drugs and also there is Stevens-Johnson syndrome and toxic epidermal necrosis. Old drug colistin is used in superbug infection but recently *mcr-1* gene has discovered in *Escherichia coli* and *Pseudomonas aeruginosa* plasmids [21,22].

The worldwide surgical procedures (234×10^6) are increased tremendously. As for example, approximate reported cases are: Injuries 63×10^6 , malignancies 31×10^6 , congenital

anomalies 14×10^6 , Obstetrical complications 10×10^6 , Cataract and Glaucoma 8×10^6 , Perinatal conditions 7×10^6 and other like cosmetic surgeries 31×10^6 [23,24]. In Africa 15 injuries/1000 peoples/day is the highest as also in South Asia 13 injuries/1000 peoples/day [25]. Between 2009-2014, 125,378,073 surgery procedures are recorded in the United Kingdom (England, Wales, Scotland and Ireland) which means 24 procedures per 1000 peoples per year with cost of \$104.4 billion. In India 31.5×10^6 of surgical procedures were reported in 2017 (Figure 5) of which 52.4% were obstetrical and gynecological and 25.9% ophthalmological [26,27]. The cosmetic surgeries are increasing in the United States as shown in Table 1. Brest reduction and Liposuction surgeries are ahead but infections are also frequent [28].




Figure 5. Statistics of invasive surgical procedures in India during 2017.

Table 1. Types of cosmetic surgeries in the US. Further, Brest implant removal (0.27×10^5), Facelift (1.25×10^5), Tummy tuck (1.29×10^5) surgeries appear increasing (<https://www.plasticsurgery.org> as assessed on 26.04.2018) African American has more heart attach (19.7%) than White American (10.9%) and much higher than Asian American (7.1%).

Total Cosmetic Procedures in the United States in 2017= 17.5×10^6					
Cosmetic Minimally Invasive Procedures			Cosmetic Surgical Procedures		
Botulinum type A	7.2×10^6	2% u	Breast Augment	0.3×10^6	3% u
Soft Tissue Fillers	2.7×10^6	3% u	Liposuction	0.24×10^6	5% u
Chemical peel	1.4×10^6	1% u	Nose Reshaping	0.2×10^6	2% d
Laser Hair Remover	1.1×10^6	2% d	Eyelid Surgery	1.3×10^6	0
Microdermabrasion	0.7×10^6	4% d	Breast Reduction	5.8×10^6	11% u

Wound infections are generally occurred by drug resistant *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumonia*, *Acinetobacter baumannii*, *Prividencia stuartii*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Morganella morganii* and *Proteus mirabilis*, etc. Gram positive and Gram negative bacteria [25,26]. Many pathogens are ESBLs and blaTEM, blaCTX-M, blaNDM-1, aacA1, catB3, strAB, sul1/2, arr3, aphA2, aadA4 and ermB genes were reported in plasmids and chromosomes as recently were demonstrated by full length plasmid DNA

sequencing (Table 2). Majorities of surgeries of intestine are greatly affected after surgeries being 2×10^{12} gut bacteria reside there and many are drug resistant [26]. The *Clostridium difficile* Infections (CDI) during colorectal surgeries has increased tremendously irrespective of hospital setting [27,28]. Inflammatory Bowl Syndromes (IBD) generally persist CDI and after surgery many patients have returned to hospital with CDI with ermB genes in plasmids and chromosomes giving resistant to clindamycin, erythromycin, ciprofloxacin, tobramycin and gentamycin but

sensitive to ceftizidime. *Clostridium sordelli* on the other hand has pCS1 plasmid with toxin TcsL gene as well as ermB DNA methylase gene and capable of conjugative gene transfer involving cst locus [29]. *Clostridium perfringens* carry on the other hand tetracycline resistant 45-140 kb pCW3 and pXO1/2 plasmids encoding toxin (Beta-toxin) as well as *mdr* genes. Other suggested phiCD211-like 131 kb bacteriophages genome insertion in *Clostridioides difficile*

(5% prevalence) activating multidrug-resistant AcrB/D/F drug efflux genes [30]. *Enterococcus faecium* infections during surgery is also evident and such strains carry 60-100 kb plasmids like pAD1, pMG1, pPD1, pMG2201, pWZ1668, pJEG043, pS177, pE856 and pRE25 conferring gentamycin, erythromycin and or vancomycin resistance (Table 2 for large MDR plasmids) [31].

Table 2. Generation of multidrug resistant plasmids with diversified *mdr* genes in superbugs.

Plasmids	Accession	Length	Multidrug resistant genes	Pathogens
pLW043	AE017171	59 kb	Dhfr, GNAT, aacA-aphD (6'-2''), vanR/S/H, vanA, vanB, vanY/Z, blaTEM, blaR1, blaI	<i>Staphylococcus aureus</i>
pSD107	JX566770	107 kb	aadA1, dhfr, strB, blaTEM, sul2, aph6'-1d	<i>Enterobacter aerogenes</i>
pS121-1a	CP022170	192 kb	mexC, aac6'-1b, cmlA5, ANT3''-1a, dhfr, aac6'-1b-cr, OXA1, sul1, mphE 2', floR	<i>Aeromonas sulmonica</i>
pTW9	AB563188	85 kb	ABC, bcrD, ermB, vanY/X, vanA, vanS/R, blaTEM	<i>Enterococcus faecalis</i>
pEGY1mcr-1	CP023143	229 kb	Aac3'-IIa, EmaA, TelA/B/F, tetA, mcr-1, ANT3''-Ia, cmlA, sul1, floR	<i>Escherichia coli</i>
P1068-KPC	MF168402	146 kb	CTX-M-65, TEM-1, SHV-12, KPC-2, MerA/C, RmtB	<i>Klebsiella pneumoniae</i>
PSHE-CTX-M	CP022359	193 kb	CTX-M-15, aac3'-IIa, CusA, tetA, aph3''-1d, aph3''-1b, sul1, (Vit*)	<i>Shewanella bicestrii</i>
pECAZ155_KPC	CP019001	272 kb	KPC, mphA, sul1, aac6'-II, cmlA, aph6'-1d, CMY-2, MFS, tetB, aac6'-1a	<i>Escherichia coli</i>
pEA19081	KX976485	79.8 kb	vanH, VanA, vanBm, FosB, vanY, vanS/R, vanZ	<i>Enterococcus avium</i>
pKP13f	CP004000	295 kb	Sul1, QacE, TEM-1, OXA-9, aad3'', sul2, CTX-M-2, aac6'-Ia, TerX/X/A	<i>Klebsiella pneumoniae</i>
pAUSMDU8141	CP022697	149 kb	MFS, sul1, catA2, tetD, TEM-1, aac3'-Ia	<i>Citrobacter farmeri</i>
pKN-LS6	NC_021654	246 kb	catA1, dhfr, sul1, mphA, MFS, ABC, silP/E/A/B, arsH/A, cusB/C/S	<i>Klebsiella pneumoniae</i>
pHXY0908	KM877269	249 kb	Aad, floR, aac6', aac3', blaOXA, catB, arr3, sul1, cmlA, aphA1	<i>Salmonella enterica</i>
pRJ119-NDM1	KX636095	335 kb	Ble, TEM, cobS, aac6', sul1, cusA, arsD, dhfr, qnr, tetA, NDM1, aph3', sul, arsH	<i>Klebsiella pneumoniae</i>
P1	NC_019375	180 kb	blaVIM, aacA7, dhfr, ANT3', blaSHV-5,	<i>Providencia stuartii</i>

			sul1, aph3'	
pOZ176	KC543497	501 kb	Ter2, OXA-10, MFS, TEM-8, ble, catB3, aac6'. IMP-9, neo	<i>Pseudomonas aeruginosa</i>
pKPx-2	AP012056	141 kb	Aac3'/6', catB4, tetA, sul2, OXA-1, CTX-M, TEM-1, strAB, qnrB	<i>Klebsiella pneumoniae</i>
pHX40908	KM877269	249 kb	Aad, floR, hph, aac6'/3', OXA-1, catB3, arr3, sul1, cmlA	<i>Salmonella enterica</i>

DISCUSSION

Bacteria present in air, water and every matters that associated with air and water [10]. We now see how it is advisable for preventing bacterial contamination during invasive surgery and burn. First, we must be aware of MRSA *Staphylococcus aureus* infections which are not only carry MDR plasmids but also "MDR Islands" in chromosome and it is almost death signal in case of burn patient's infection. Again drug cocktail is must be given which is injurious liver, kidney and intestine and more sadly many antibiotics has acquired drug induced expression of MDR genes like blaAMP-C gene induction by imipenem, a drug mostly used in MDR infections between 1985 to till date [9]. Imipenem now has replaced by potent derivatives like meropenem and doripenem that block bacterial cell wall peptidoglycan synthesis.

Presently, we most blame *Acinetobacter baumannii*, a Gram(-) bacteria being highly resistant to disinfections and its spore can withstand in surgical instruments for months. Essentially, ampicillin, cefotaxime, imipenem, ciprofloxacin, azithromycin, streptomycin, tetracycline, chloramphenicol are useless as single plasmid could carry 10-15 mdr genes (accession nos. CP001921, CP002522, AP013357). Importantly, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* are dangerous as have acquired mexAB/CD/EF and smeDEF drug efflux genes cluster respectively as well as tetA/C drug efflux genes other than few bla gene isomers and acetyl- or phospho-transferases (accessions nos. AM743169; KC543497; HE798556). *Klebsiella pneumoniae* is another culprit that cause nosocomial infections and we see hundreds of potent MDR plasmids have been sequenced today to clarify that during surgery such bacterial infections could be deathful (accession nos. NC_021232; KT185451). In India clinical isolates of *E. coli* have blaPER, blaVIM and blaTEM where as in *P. aeruginosa* blaOXA-23, blaNDM-1, blaOXA-51 are very prevalent mdr genes [32]. In liver cancer surgery, a shift of gut microbiota has been observed where probiotic therapy could be beneficial and likely indicates drastic action of prophylactic antibiotics on gut microbiota population [33]. Other than *S. aureus* well characterized chromosomally encoded mdr determinants (SECmec), *Salmonella typhi* Asian isolates have shown to harbor both

chromosomal and plasmid encoding mdr genes giving resistant to fluoroquinolones, 3rd generation cephalosporins and aminoglycosides [34]. A Kolkata study between 1998-2012 indicated the decrease in ampicillin resistance but increase in ciprofloxacin resistance among *Salmonella enterica* clinical isolates but our recent study had demonstrated that blaTEM, blaCTX-M and aac6'-1b genes were very frequent in most environmental Enterobacteriaceae [10,35].

CONCLUSION

We conclude that surgical infections will be problem even we use antibiotics. But some reports advice ampicillin, chloramphenicol, ciprofloxacin and streptomycin as preoperative prophylaxis which totally wrong this days. Main reason is high cost of carbapenem and new aminoglycosides and peptide antibiotics (100 times) which is very hard to pay by poor patients of Asia, Africa and Latin America. Sadly, Drug Sensitivity Tests are not mandatory in India and patients are given repeated antibiotic doses which is totally devastating for health [36-40]. Doctors sometime prescribe high cost vitamins and probiotics to patients but many good drug companies have low cost such nutrients and medicines for poor countries. WHO and CDC guidelines are there but Nursing Homes hardly follow such guidelines and Government has no control of such malpractices in poor nations [37]. Medical cost drags millions peoples into poverty line each year and is very catastrophic in the light of 21st century civilization. Many surgeries in India cost much less than developed world. As for example, liposuction in the USA cost rupees 483941, in the UK cost rupees 387153 but in the India cost rupees 64000. Thus many tourists have done plastic surgeries in India. Global surgery procedures are 234 million and in India 31.5 million. So we should find alternative to antibiotics. Phyto-antibiotics, phage therapy, enzybiotics, gene therapeutics and nanotechnology are the driving forces shaping next generation antimicrobials to prevent infections during surgery [41-48].

ACKNOWLEDGEMENT

I thank Dr. Jagat Bhusan Medda, President of Oriental Association of Education and Research for funding and Dr. Bidyut Bandhopadhyay for critical suggestions during preparation of the review. Special thanks to Dr. Scott Pantel for providing Surgical Data of India.

REFERENCES

- Chakraborty AK (2016) Multi-drug resistant genes in bacteria and 21st Century problems associated with antibiotic therapy. *Biotechnol Ind J* 12: 114.
- Tarchini G, Liao KH, Solomkin JS (2017) Antimicrobial stewardship in surgery: Challenges and opportunities. *Clin Infect Dis* 64: S112-S114.
- Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, et al. (2017) Centers for Disease Control and Prevention guideline for the prevention of surgical site infection-2017. *JAMA Surg* 152: 784-791.
- Khan MA, Ansari MN, Bana S (1985) Post-operative wound infection. *Ind J Surg* 47: 383.
- Bush K, Macielag MJ (2010) New β -lactam antibiotics and β -lactamase inhibitors. *Expert Opin Ther Patents* 20: 12771293.
- Chakraborty AK (2016) Complexity, heterogeneity, 3D structures and transcriptional activation of multi-drug resistant clinically relevant bacterial beta-lactamases. *Trends Biotechnol Open Access* 2: 1-001.
- Chakraborty AK, Maity M, Patra S, Mukherjee S, Mandal T (2017) Complexity, heterogeneity and mutational analysis of antibiotic inactivating acetyl transferases in MDR conjugative plasmids conferring multi-resistance. *Res Rev J Microbiol Biotechnol* 6: 28-43.
- Li XZ, Plésiat P, Nikaido H (2015) The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria. *Clin Microbiol Rev* 28: 337-418.
- Chakraborty AK (2015) High mode contamination of multi-drug resistant bacteria in Kolkata: Mechanism of gene activation and remedy by heterogeneous phyto-antibiotics. *Ind J Biotechnol* 14: 149-159.
- Chakraborty AK (2017) Multi-drug resistant bacteria from Kolkata Ganga River with heterogeneous MDR genes have four hallmarks of cancer cells but could be controlled by organic phyto-extracts. *Biochem Biotechnol Res* 5: 11-23.
- Chakraborty AK (2017) Mechanisms of AMR: Bacteria won the battle against antibiotics. *Insights Biomed* 2: 19.
- Ahmadjian PS (2000) Symbiosis: An introduction to biological associations. 2nd Edn. Oxford University Press (ISBN 0-19-511807-3).
- Hill MJ (1997) Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 6: S43-S45.
- Chakraborty AK (2017) *mdr* genes are created and transmitted in plasmids and chromosomes to keep normal intestinal microbiota alive against high dose antibiotics - A hypothesis. *J Mol Med Clin Appl* 2: 109.
- Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: A laboratory manual. 2nd Edn. Cold Spring Harbor Laboratory Press, New York.
- Chakraborty AK, Cichutek K, Duesberg PH (1991) Transforming function of proto-*ras* genes depends on heterologous promoters and is enhanced by specific point mutations. *Proc Natl Acad Sci U S A* 88: 2217-2221.
- Chakraborty AK, Zink MA, Boman BM, Hodgson CP (1993) Synthetic retrotransposon vectors for gene therapy. *FASEB J* 7: 971-977.
- Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 74: 5463-5467.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. *Nucleic Acids Res* 25: 3389-3402.
- Bairoch A, Apweiler R (2000) The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. *Nucleic Acids Res* 28: 45-48.
- Chakraborty AK (2016) *In silico* analysis of hotspot mutations in the bacterial NDM-1 and KPC-1 carbapenemases that cause severe MDR phenotypes. *Biochem Biotechnol Res* 4: 17-26.
- Chakraborty AK (2017) Colistin drug resistant determinant *mcr-1* gene spreads in conjugative plasmids creating huge confusion for the treatment of multi-drug resistant infections. *Am Res J Biotechnol* 1: 1-9.
- Abbott TEF, Pearse RM, Fowler AJ, Dobbs TD, Harrison EM, et al. (2017) Frequency of surgical treatment and related hospital procedures in the UK: A national ecological study using hospital episode statistics. *Br J Anesth* 119: 249-257.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. (2015) Heart disease and strokes statistics-2015 update: A report from the American Heart Association. *Circulation* 131: e29-322.
- Manyahi J, Matee MI, Majigo M, Moyo S, Mshana SE, et al. (2014) Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili national hospital, Tanzania. *BMC Res Notes* 7: 500.
- Anvikar AR, Desmukh AB, Karykarte RP, Damle AS, Patwardhan NS, et al. (1997) A one year prospective study of 3280 surgical wounds. *Ind J Med Microbiol* 17: 129-132.
- Aquina CT, Probst CP, Becerra AZ, Hensley BJ, Iannuzzi JC, et al. (2016) High variability of nosocomial *Clostridium difficile* infection rates across hospitals after colorectal resection. *Dis Colon Rectum* 59: 323-331.
- Kaiser AM, Hogen R, Bordeianou L, Alavi K, Sudan R, et al. (2015) *Clostridium difficile* infection from a surgical perspective. *J Gastro Surg* 19: 1363-1377.
- Vidor CJ, Watts TD, Adams V, Bulach D, Couchman E, et al. (2018) *Clostridium sordellii* pathogenicity locus plasmid pCS1-1 encode a novel Clostridial conjugation locus. *MBio* 9: pii:e01761-17.
- Garneau JR, Sekulovic O, Dupuy B, Soutourina O, Monot M, et al. (2018) High prevalence and genetic diversity of large phiCD211 (phiCDIF1296T)-like prophages in *Clostridioides difficile*. *Appl Environ*

- Microbiol 84.Pii: e02164-2017.
31. Takeuchi K, Tomita H, Fujimoto S, Kudo M, Kuwano H, et al. (2005) Drug resistance of *Enterococcus faecium* clinical isolates and the conjugal transfer of gentamycin resistance traits. FEMS Lett 243: 347-354.
 32. Pragasam AK, Vijayakumar S, Bakthavatchalam YD, Kapil A, Das BK, et al. (2016) Molecular characterization of antimicrobial resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* during 2014 and 2015 collected across India. Ind J Med Microbiol 34: 433-441.
 33. Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, et al. (2016) Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A 113: 1306-1315.
 34. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, et al. (2018) Emergence of an extensively drug resistant *Salmonella enterica* serovar *typhi* clone harbouring a promiscuous plasmid encoding resistance to fluoroquinolones and third generation cephalosporins. MBio 9. Pii: e00105-18.
 35. Das S, Samajpati S, Ray U, Roy I, Dutta S (2017) Antimicrobial resistance and molecular subtypes of *Salmonella enterica* serovar *typhi* isolated from Kolkata, India over a 15 years period 1998-2012. Int J Med Microbiol 307: 28-36.
 36. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, et al. (1987) Bacterial biofilms in nature and disease. Annu Rev Microbiol 41: 435-464.
 37. Chakraborty AK (2017) Mechanism of AMR: *mdr* genes and antibiotics decoys retard the new antibiotic discovery against superbugs. Nov Approv Drug Des Dev 2: 555576.
 38. Kahrstrom CT, Pariente N, Weiss U (2016) Intestinal microbiota in health and disease. Nature 535: 47.
 39. Chen Y, Yang F, Lu H, Wang B, Chen Y, et al. (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54: 562-572.
 40. Qin N, Yang F, Li A, Prifti E, Chen Y, et al. (2014) Alteration of the human gut microbiome in liver cirrhosis. Nature 513: 59-64.
 41. Sahoo N, Manchikanti P, Dey SH (2011) Herbal drug patenting in India: IP potential. J Ethnopharmacol 137: 289-297.
 42. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417-433.
 43. Drawz SM, Bonomo RA (2010) Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23: 160-201.
 44. Chakraborty AK (2018) Roles of vitamin metabolizing genes in multidrug-resistant plasmids of superbugs. BioRxiv.
 45. Chakraborty AK, Roy T, Mondal S (2016) Development of DNA nanotechnology and uses in molecular medicine and biology. Insights Biomed 1: 13.
 46. Chakraborty AK (2017) Enzybiotics, a new class of antimicrobials targeted against multidrug-resistant superbugs. Nov Appo Drug Des Dev 2: 555592.
 47. Fernandes, S, Proença D, Cantante C, Silva FA, Leandro C, et al. (2012) Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant *Staphylococcus aureus*. Microb Drug Resist 18: 333-343.
 48. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, et al. (2018) Gene therapy comes of age. Science 359. pii: eaan4672.